Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Cancer Therapies02:49

Cancer Therapies

3.0K
3.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

640
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
640

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma.

Cancer research·2026
Same author

Quantifying single-cell responses to irradiation in 3D.

Frontiers in bioengineering and biotechnology·2026
Same author

Cell Cycle-Specific Regulation of Centrosome Clustering Dynamics in Cancer Cells by the Multifunctional Kinesin HSET.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Genetic resonance in the p53 signaling network.

Cell systems·2026
Same author

DNA damage checkpoints balance a tradeoff between diploid- and polyploid-derived arrest failures.

Cell reports·2025
Same author

Decoding the Central Dogma: Quantitative Insights into Transcription and Translation Dynamics in the p53-Mediated DNA Damage Response.

Journal of molecular biology·2025
Same journal

A native sulfur deposit in Gale crater, Mars.

Science (New York, N.Y.)·2026
Same journal

Coordinated demise of harmful algal blooms.

Science (New York, N.Y.)·2026
Same journal

Genetic effects put into context.

Science (New York, N.Y.)·2026
Same journal

Bacteria share proteins to survive antibiotics.

Science (New York, N.Y.)·2026
Same journal

Impacts shaped Earth's first continents.

Science (New York, N.Y.)·2026
Same journal

Erratum for the Report "Covalently bonded single-molecule junctions with stable and reversible photoswitched conductivity" by C. Jia <i>et al</i>.

Science (New York, N.Y.)·2026
関連記事をすべて見る

関連する実験動画

Updated: Mar 24, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K

抗がん治療のスケジュール依存の相互作用

Sheng-Hong Chen1, William Forrester2, Galit Lahav1

  • 1Department of Systems Biology, Harvard Medical School, Boston, MA, USA.

Science (New York, N.Y.)
|March 12, 2016
PubMed
まとめ
この要約は機械生成です。

腫瘍抑制剤p53を活性化させるが,がん細胞死に対する効果はp53に依存する.

さらに関連する動画

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.6K

関連する実験動画

Last Updated: Mar 24, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.6K

科学分野:

  • 腫瘍学
  • 分子生物学
  • 細胞シグナリング

背景:

  • 多くのがんではMDMXが過剰発現し,腫瘍抑制剤p53を抑制する.
  • MDMX阻害剤はp53を再活性化し,DNAを損傷する薬剤の有効性を高める可能性があります.
  • p53シグナル伝達とDNA損傷に対するMDMX阻害の影響に関する定量的な理解は欠けている.

研究 の 目的:

  • MDMXの抑制がp53信号経路にどのように影響するかを定量的に調査する.
  • 癌細胞がDNAを損傷する物質に対するMDMX抑制の影響を決定する.

主な方法:

  • MDMXの枯渇後の単細胞におけるp53蓄積の動態を観察するために,生細胞画像を用いた.
  • この研究では,p53蓄積の異なる段階におけるDNA損傷に対する細胞の異なる反応を分析した.

主要な成果:

  • MDMXの枯渇は,p53の蓄積の2つの異なる段階を誘導した:最初のポスミトスパルスと,その後の低幅の振動.
  • DNAの損傷に対する細胞の反応は,これらの段階の間に大きく変化した.
  • 第"段階ではMDMXの減少が DNAの損傷と連携して 細胞死を誘発します
  • 第2段階では,MDMXの減少により,DNA損傷による細胞死が抑制されました.

結論:

  • DNA損傷に対するMDMX抑制のタイミングは,治療結果にとって極めて重要です.
  • 組み合わせ治療の最適化には,p53信号のダイナミクスと細胞状態を理解することが不可欠です.
  • この研究は,MDMX阻害剤とDNAダメージを与える物質を含む二重薬剤投与のスケジュールを定めるための定量的な基礎を提供します.